Optimizing Outcomes: Bevacizumab with Carboplatin and Paclitaxel in 5110 Ovarian Cancer Patients—A Systematic Review and Meta-Analysis
Pharmaceuticals · 21.08.2024 · 17 (8) · 1095
DOI: 10.3390/ph17081095 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 21.08.2024. Verfasst von Yu Jin Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Ewha Womans University, Seoul 03760, Republic of Korea. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background/Objectives: The study aimed to evaluate the efficacy and safety of incorporating bevacizumab into the combination therapy of carboplatin and paclitaxel for epithelial ovarian cancer and other clinical applications.
Methods
A systematic review was conducted following PRISMA guidelines using keyword searches in PubMed, Embase, Cochrane Library, CINAHL, ClinicalTrials.gov, and ICTRP until February 2024. Randomized controlled trials (RCTs) comparing carboplatin and paclitaxel with and without bevacizumab in ovarian cancer patients were included. Efficacy outcomes were overall survival (OS) and progression-free survival (PFS), as described by hazard ratios (HRs). Safety outcomes were analyzed with risk ratios (RRs) for 16 adverse events.
Results
Seven RCTs (n = 5110) were included. The combination with bevacizumab significantly improved PFS (HR: 0.73; 95% confidence interval: 0.58, 0.92; p = 0.008). The chemotherapy group receiving bevacizumab with carboplatin and paclitaxel showed a significantly higher incidence of hypertension, non-CNS bleeding, thromboembolic events, GI perforation, pain, and proteinuria.
Conclusions
The combination of carboplatin, paclitaxel, and bevacizumab improves PFS compared to the regimen without bevacizumab, but it raises significant safety concerns. Clinical management should consider adverse event prevention by vigilantly monitoring blood pressure, signs and symptoms of bleeding, thromboembolism, GI perforation, and pain to balance the therapeutic benefits with the potential risks of this combination therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmacy, Ewha Womans University, Seoul 03760, Republic of Korea.
- Graduate School of Life and Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea.
- Department of Pharmacy, Ewha Womans University Seoul Hospital, Seoul 07804, Republic of Korea.
- Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea.
ORCID-Profile: Yu Jin Kim, Hee Min Lee, Sandy Jeong Rhie
Zitieren
APA
Kim, Y. J., Lee, H. M., Lee, G. E., Yoo, J. H., Lee, H. J., & Rhie, S. J. (2024). Optimizing Outcomes: Bevacizumab with Carboplatin and Paclitaxel in 5110 Ovarian Cancer Patients—A Systematic Review and Meta-Analysis. Pharmaceuticals, 17(8), 1095. https://doi.org/10.3390/ph17081095
Vancouver
Kim YJ, Lee HM, Lee GE, Yoo JH, Lee HJ, Rhie SJ. Optimizing Outcomes: Bevacizumab with Carboplatin and Paclitaxel in 5110 Ovarian Cancer Patients—A Systematic Review and Meta-Analysis. Pharmaceuticals. 2024;17(8):1095. doi:10.3390/ph17081095
BibTeX
@article{Kim2024,
author = {Kim, Yu Jin and Lee, Hee Min and Lee, Ga Eun and Yoo, Jin Hui and Lee, Hwa Jeong and Rhie, Sandy Jeong},
title = {Optimizing Outcomes: Bevacizumab with Carboplatin and Paclitaxel in 5110 Ovarian Cancer Patients—A Systematic Review and Meta-Analysis},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {8},
pages = {1095},
doi = {10.3390/ph17081095}
}
EUVIMED